Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib in recurrent ovarian, fallopian tube, or peritoneal cancer
NCT00278343Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2006
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of cediranib in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Primary endpoint: Objective Tumor Response Rate at 16 weeks. Started Apr 2006; status: completed.
02
Drugs
cediranib
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00278343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00278343.